Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten) failed. The phase III study was evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback